Homology Medicines Inc
FIXX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.02M
Close$
$-0.34
136.7% downside
Current Fair Value
136.7% downsideOvervalued by 136.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.02 Million |
|---|---|
| Enterprise Value | $-36,739,255.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.42 |
| Beta | -0.11 |
| Outstanding Shares | 14,095,371 |
Return
| Return on Equity | 88.21% |
|---|---|
| Return on Assets | 64.16% |
| Return on Invested Capital | 40.17% |
Valuation & Multiples
| P/E Ratio | 4.69 |
|---|---|
| PEG | -4.69 |
| Price to Sales | - |
| Price to Book Ratio | 0.31 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.73 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.3 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Homology Medicines Inc
CEO: Arthur Tzianabos